Skip to content
The Policy VaultThe Policy Vault

Actimmune (interferon gamma-1b)United Healthcare

Severe, malignant osteopetrosis

Initial criteria

  • Diagnosis of severe, malignant osteopetrosis

Reauthorization criteria

  • Patient does not show evidence of progressive disease while on Actimmune

Approval duration

12 months